RxDoctor Payments Data

Brittany Hall

Nurse Practitioner · Hobart, INNPI 1841704996

Payments from drug & device makers

$5,978in general payments, 2019–2025

Across 338 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$873
  • Merck$763
  • Amgen$739
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$641
  • Boehringer Ingelheim$444
  • Johnson & Johnson$361
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,978 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$24,758
Medicare patients
229
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan115$74,690
EliquisApixaban80$53,407
BrilintaTicagrelor73$38,135
XareltoRivaroxaban23$17,047
Repatha SureclickEvolocumab18$15,600
Ranolazine ErRanolazine12$1,306
Rosuvastatin Calcium25$524
Metoprolol Succinate77$406
ClopidogrelClopidogrel Bisulfate71$324
Carvedilol45$266
Amlodipine Besylate27$194
Atorvastatin Calcium48$156
Amiodarone Hcl13$147
Losartan Potassium29$144
Furosemide48$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$873$74,690115 claims
PfizerEliquis$251$53,40780 claims
AstraZenecaBrilinta$349$38,13573 claims
Johnson & JohnsonXarelto$361$17,04723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →